- Stephen Fry is nominated to the Lonza Board for his extensive track record in the pharma industry and deep experience in performance culture and organisational transformation
- Subject to his election at the Lonza AGM in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committee
Stephen brings deep pharmaceutical industry experience, a global leadership perspective and strong expertise to the Board. Stephen spent more than three decades at Eli Lilly and Company, where he held a broad range of international, operational and executive leadership roles, ultimately serving as Executive Vice President and Chief Human Resources Officer for 12 years. In this role, he led large‑scale organisational transformation, shaped high‑performance cultures and helped navigate the company through significant change. Stephen is also a Member of the Board of Trustees at the University of Indianapolis (US).
Jean-Marc Huët, Chairman of the Board, Lonza, commented: “The Board of Directors extends its warmest congratulations to Stephen for his nomination to the Board. Stephen brings extensive international experience, combined with a strong track record in organisational governance, succession planning and people strategy development, all of which form a valuable complementary fit with the capabilities of our other Board members. Stephen will play an important role in helping develop and embed our performance culture. This will support our ambition to attract and retain world-leading talent and bring our high-performing teams to the next level.”
